Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Avadel Pharmaceuticals plc is a biopharmaceutical company specializing in developing and commercializing treatments for rare central nervous system disorders. Its core product, LUMRYZ, is an extended-release sodium oxybate formulation for narcolepsy-related cataplexy and excessive daytime sleepiness in patients aged seven and older. Avadel leverages proprietary drug delivery technologies and operates primarily in the U.S. market, focusing on improving patient compliance and safety through innovative dosing regimens and regulatory exclusivities.
This description was generated via AI from an annual report. Updated about 1 year ago.